Withdrawal Archives - CED Foundation

Capsaicin Cream Treats Cannabinoid Hyperemesis Syndrome in Adolescents

June 20, 2019 Adolescents, Adverse Effects, Anxiety, Cannabinoids, Cannabis, Cannabis Hyperemesis Syndrome, Cannabis Science, Cannabis Use Disorder (CUD), Capsaicin, CB1, CB2, Heavy Use, Science, THC, Withdrawal

Capsaicin Cream for Treatment of CHS adolescent

Researchers have found that capsaicin cream is an effective and safe method of treating cannabinoid hyperemesis syndrome (CHS) in adolescents. Capsaicin cream has previously been shown to be effective at treating CHS in adults but adolescents have previously been treated with haloperidol, a drug known to have serious side effects. Capsaicin cream offers a much safer and more cost-effective method of treatment for adolescents.

View this review (yellow link) or download:

Capsaicin Cream for Treatment of CHS adolescent Download

This paper is also stored here: http://bit.ly/2F8Gtcc inside the CED Foundation Archive

To explore related information, click the keywords below:

Cannabinoid Hyperemesis Syndrome is Frequently Misdiagnosed as Cyclic Vomiting Syndrome

June 20, 2019 Abuse, Adverse Effects, Anxiety, Cannabinoids, Cannabis, Cannabis Education, Cannabis Hyperemesis Syndrome, Cannabis Science, Cannabis Use Disorder (CUD), CBD, Heavy Use, THC, Withdrawal

Association of Marijuana Use and Cyclic Vomiting Syndrome

A recent study has found that a subset of patients diagnosed with Cyclic Vomiting Syndrome actually suffers from Cannabinoid Hyperemesis Syndrome. Cannabinoid Hyperemesis Syndrome is a rare condition that primarily occurs in daily, long-term users of cannabis, more common among males than females. Chronic cannabis consumers should inform their physicians of any illicit drug use, as well as any cannabis consumption, during routine check-ups and/or emergency room visits, to ensure accurate diagnoses can be made.

View this review (yellow link) or download:

Association of Marijuana Use and Cyclic Vomiting Syndrome Download

This paper is also stored here: http://bit.ly/2F9YS8u inside the CED Foundation Archive

To explore related information, click the keywords below:

The Education of Dispensary Staff is Varied and Lacks Regulation

June 17, 2019 Adolescents, Anti-inflammatory properties, Anxiety, Arthritis, Behavior change, Cannabinoids, Cannabis, Cannabis Education, Cannabis News, CBD, Citizen Science, Depression, Dispensaries, Elderly, Future Medicine, History, Legislation, Mental Health, Mood, Neuropathy, Obesity, Pain, Pediatrics, Politics, Regulation, Science, Social Equity, Social Justice, Stigma, THC, Withdrawal, Women in Cannabis

Training and Practices of Cannabis Dispensary Staff

How much medical training does your local budtender possess? An online survey sent to medical marijuana dispensary staff reported only 55% of staffers had any formal training for their position, with 20% reporting some background in medical/scientific training. The analysis reported that many among the dispensary staff are recommending cannabis choices that are consistent with current evidence, but some are recommending strains that are either ineffective or exacerbate a patient’s condition. The findings of this study stress the importance of consistent and well-regulated training of dispensary staff.

View this review (yellow link) or download:

This paper is also stored here: http://bit.ly/2FfJNSC inside the CED Foundation Archive

To explore related information, click the keywords below:

Video: Cannabis For Symptoms of chronic pain, seizures, and inflammation

June 10, 2019 Adverse Effects, Anti-inflammatory properties, Anxiety, Arthritis, Cannabinoids, Cannabis, Cannabis Education, Cannabis News, Cannabis Science, CB1, CB2, CBD, Citizen Science, Depression, Dronabinol, Elderly, Flavonoids, Future Medicine, Heavy Use, History, IBS, Insomnia, Neuropathy, Occasional Use, Opiates, Overdose, Pain, Psychosis, Schizophrenia, Science, Sleep, Stigma, THC, Withdrawal

View this review (yellow link) or download:

Preferences for Medical Marijuana over Prescription Medications Among Persons Living with Chronic Conditions- Alternative, Complementary, and Tapering Uses Download

This paper is also stored here: http://bit.ly/2l4sexZ inside the CED Foundation Archive

To explore related information, click the keywords below:

Guanfacine reducing cannabis withdrawal symptoms?

June 10, 2019 Adverse Effects, Cannabinoids, Cannabis, Cannabis Science, Cannabis Use Disorder (CUD), Elderly, Future Medicine, Heavy Use, Products, Withdrawal

Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers

A study performed on daily cannabis users with cannabis use disorder (CUD) found evidence for Guanfacine to reduce the irritability and disturbances to sleep, characteristic of cannabis withdrawal. It is potentially a viable, improved alternative to Lofexidine, another treatment for CUD which happens to result in some adverse effects, including drowsiness, dizziness, and altered food intake. However, beyond these effects, while Lofexidine reduced cannabis self-administration following abstinence, Guanfacine did not in this study. Regardless, further research on the therapeutic effects of Guanfacine may be worthwhile and could help reduce cannabis cravings following withdrawal.

For the full review & to explore related work:

Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers Download

This paper is also stored here: http://bit.ly/2wsKbZh inside the CED Foundation Archive

Combatting Cannabis Withdrawal Syndrome

June 5, 2019 Anxiety, Depression, DSM-5, Heavy Use, Sleep, Withdrawal

DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults

Cannabis withdrawal syndrome affects approximately 12.1% of heavy cannabis users and is characterized by symptoms such as nervousness/anxiety, hostility, sleep difficulty, and depressed mood. It has increased prevalence among those suffering from mood disorders, anxiety disorders, and personality disorders. This new data should emphasize the need for physicians to exercise caution when recommending cannabis to individuals who may end up consuming cannabis heavily, and who also suffering from mood, anxiety, or personality disorders

http://bit.ly/2XeL7wl